| 摘要: |
| ［摘要］ 辅助内分泌治疗（AET）是激素受体阳性乳腺癌患者的有效治疗策略，可使患者获得显著生存收益，降低复发风险。为了确定合适的治疗策略，早期乳腺癌AET应考虑到患者在诊断时的疾病复发的个体风险和绝经状态。围绝经期人群是乳腺癌高发人群。该文重点综述围绝经期激素受体阳性乳腺癌患者AET相关研究进展。 |
| 关键词: 乳腺癌 围绝经期 辅助内分泌治疗 |
| DOI：10.3969/j.issn.1674-3806.2023.12.19 |
| 分类号:R 737.9 |
| 基金项目:国家自然科学基金资助项目（编号：82060543） |
|
| Research progress of adjuvant endocrine therapy for perimenopausal hormone receptor-positive breast cancer |
|
LUAN Bi-qing, GE Fei
|
|
Department of Breast Surgery, the First Affiliated Hospital of Kunming Medical University, Yunnan 650032, China
|
| Abstract: |
| ［Abstract］ Adjuvant endocrine therapy(AET) is an effective treatment strategy for patients with hormone receptor-positive breast cancer and can make the patients obtain significant survival benefits and reduce the risk of recurrence. To determine the most appropriate treatment strategy, AET for early breast cancer should consider a patient′s risk of disease recurrence and menopausal status at the time of diagnosis. The population in perimenopause is the population with high incidence of breast cancer. This paper focuses on the relevant research progress of AET for perimenopausal hormone receptor-positive breast cancer patients. |
| Key words: Breast cancer Perimenopause Adjuvant endocrine therapy(AET) |
